Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11000743 | 0.84 | HPGD (0.83) | HPGDMEN1KMT2APOLBHTT | |
| SCHEMBL460093 | 0.78 | HPGD (0.70) | HPGDMEN1KMT2APOLBHTT | |
| SCHEMBL694478 | 0.78 | HTT (0.52) | HPGDMEN1KMT2AHTTALDH1A1 | |
| SCHEMBL789015 | 0.77 | HPGD (0.50) | HPGDMEN1KMT2APOLBHTT | |
| SCHEMBL3467606 | 0.77 | HPGD (1.00) | HPGDMEN1KMT2APOLBHTT | |
| SCHEMBL20032 | 0.76 | KEAP1 (0.60) | HPGDHTTALDH1A1KIF11MAPT | |
| SCHEMBL3872525 | 0.75 | HPGD (0.68) | HPGDMEN1KMT2APOLBHTT | |
| SCHEMBL14358427 | 0.75 | HPGD (0.68) | HPGDMEN1KMT2APOLBHTT | |
| SCHEMBL9464414 | 0.75 | HPGD (0.68) | HPGDMEN1KMT2APOLBHTT | |
| SCHEMBL14358426 | 0.75 | HPGD (0.68) | HPGDMEN1KMT2APOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| EP-1423391-B8 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| US-7164024-B2 | Muscarinic acetylcholine receptor antagonist; Parkinson's disease; dystonia; analgesics; irritable bowel syndrome | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-16 | — | — | US | disclosed |
| EP-1423391-B1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2005-03-10 | — | — | US | disclosed |
| US-20040147506-A1 | Benzimidazolone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1423391-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| EP-1408963-A1 | 2- 5-(5-CARBAMIMIDOYL-1 i H /i -HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-04-21 | — | — | EP | disclosed |
| EP-1386920-A1 | BENZIMIDAZOLONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-02-04 | — | — | EP | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003006011-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL]-SUCCINIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
| US-4927731-A | PHOTOTHERMOGRPHY; MICROCAPSULES; STORAGE STABILITY; IMAGE CLARITY | FUJI PHOTO FILM CO., LTD. (JP) | 1990-05-22 | — | — | US | disclosed |
| EP-0143570-B1 | SILVER HALIDE COLOR PHOTOGRAPHIC MATERIAL | KONICA CORPORATION (JP) | 1988-01-27 | — | — | EP | disclosed |
| US-4548899-A | MAGENTA COUPLER | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1985-10-22 | — | — | US | disclosed |
| EP-0143570-A2 | Silver halide color photographic material | KONICA CORPORATION (JP) | 1985-06-05 | — | — | EP | disclosed |
| EP-0075117-B1 | 2H-1,2,4,6-THIATRIAZINE-1,1-DIOXIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES | BASF Aktiengesellschaft (DE) | 1985-03-13 | — | — | EP | disclosed |
| US-4428766-A | 2N-1,2,4,6,Thiatriazine-1,1-dioxides and their use for controlling undesirable plant growth | BASF AKTIENGESELLSCHAFT (DE) | 1984-01-31 | — | — | US | disclosed |
| EP-0075117-A2 | 2H-1,2,4,6-thiatriazine-1,1-dioxides, process for their preparation and their use as herbicides | BASF Aktiengesellschaft (DE) | 1983-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | CTSK, CTSS, CTSZ | HPGD 334/4885MEN1 4225/4885KMT2A 4486/4885 |
| US-20040147506-A1 | Benzimidazolone derivatives | HRH2, CCKAR, HRH4 | HPGD 1893/4885MEN1 204/4885KMT2A 2292/4885 |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | CTSK, CTSS, CTSZ | HPGD 334/4885MEN1 4225/4885KMT2A 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.